Recommended

New webinar: Overcoming critical challenges in AI-driven drug discovery
Watch on demand: Rapid cell-based profiling of multi-target anti-obesity drugs Watch here!
Download now: Unlock the power of stem cell therapy and discover the potential for new therapies for primary open-angle glaucoma
Brand new Beyond the Lab report on antibodies… Download NOW!
Webinar

Advancing obesity drug discovery: Cell-based assays for GLP-1 and the G-Suite

19 March 2025

3:00pm

Discover innovative and validated solutions for developing obesity therapeutics. These solutions enable effective screening, characterisation, and potency testing for commercial lot release of novel drugs targeting GPCRs, including GLP-1, GIP, and glucagon receptors.

The rapid advancement of obesity therapeutics, driven by breakthroughs like semaglutide (Wegovy®) and tirzepatide (Zepbound®), have accelerated the development of next-generation treatments with improved efficacy and safety. These therapies target critical GPCRs, including the GLP-1, GIP, and glucagon receptors, showcasing the potential of single, dual, and triple agonists in achieving significant weight loss and metabolic improvements.

This webinar will examine the challenges and opportunities in obesity drug discovery, with a focus on a comprehensive range of well-characterised assay solutions designed to accelerate over 100 obesity therapeutic programs worldwide.

In this webinar, join Dr. Frances Reichert, Technical Specialist for Biologics at Eurofins BioPharma Product Testing, and Shruti Kumar, Field Application Scientist at Eurofins DiscoverX, as they present a robust portfolio of pre-qualified functional assays. These assays measure cAMP, β-arrestin, and receptor internalization, enabling effective screening, selection, and characterisation of therapeutic candidates targeting obesity-related GPCRs.

Using data from key targets like GLP-1R, GIPR, and GCGR, our experts will demonstrate how these assays provide the flexibility and reliability necessary for identifying and optimising novel compounds. The benefits of integrating automation into functional, cell-based potency assays will be revealed, including improved data reproducibility, reduced variability, and significant time and cost savings for QC lot-release programs. Plus, our experts will highlight Eurofins DiscoverX’s role as a trusted partner in supporting your drug discovery programs, offering high-quality data and tailored solutions to meet your research needs.

Key learning points: 

  • Discover advanced screening and functional assays for GLP-1, GIP, glucagon, and other GPCR receptors to accelerate obesity therapeutic discovery.
  • Understand the evolving landscape of obesity drug development, including single, dual, and triple agonist approaches.
  • Learn how robust in vitro pharmacology assays provide high-quality data to optimise compound efficacy and safety.
  • Explore strategies for addressing common challenges in obesity research and enhancing the success of your programs.
  • Gain insights from real-world data demonstrating the utility of cutting-edge tools for receptor-specific profiling.
  • Understand the integration of automation in cell-based assays for improving efficiency and scalability in obesity research.

Register now to secure your place!

OUR SPEAKERS

Shruti Kumar, M.S. – Field Application Scientist, Eurofins DiscoverX

Shruti Kumar holds a master’s degree in pharmacology from Campbell University, North Carolina, specialising in bioassay development and validation. With over a decade of experience in cell-based assay development, she has built expertise in working with complex biologics and biosimilars. As a field application scientist at Eurofins DiscoverX, Kumar provides technical expertise, training, and collaborative solutions across the Asia-Pacific region, working closely with researchers and biopharma clients. She supports the adoption and integration of Eurofins DiscoverX’s cell-based assays, ensuring their seamless implementation in clinical development programs for therapeutics.

Dr Frances Reichert – Technical Specialist for Biologics, Eurofins BioPharma Product Testing, Planegg/Munich, Germany

Dr. Frances Reichert holds a Ph.D. from the University of Frankfurt and studied at the University of Applied Sciences in Bingen am Rhein, where she gained hands-on experience in antibody manufacturing and related areas. Reichert has been employed at Eurofins BPT Munich (DACH) since 2010 and is currently a technical specialist for biologics within the sales department, filling the gap between technical requirements and customer needs. Reichert has accumulated more than 10 years of experience in the development and validation of cell-based potency assays and binding ELISAs. Prior to this role, she served as Head of the Bioassay Development and Validation Department at Eurofins BPT Munich. Since 2010, she has worked as a quality control manager for QC bioassays. From 2016 onwards, she led a small team as group leader within the bioassay department, focusing on the development, qualification, validation, and transfer of various potency assays.

 

FAQs

Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.

When will the webinar take place?
The webinar will take place live on 19 March 2025 at 3PM GMT. 

I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.

What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.

How long will the webinar be?
This webinar will last for up to one hour.

What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.

Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.